GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NexGel Inc (NAS:NXGL) » Definitions » ROE %

NexGel (NexGel) ROE % : -71.95% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is NexGel ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. NexGel's annualized net income for the quarter that ended in Mar. 2024 was $-3.41 Mil. NexGel's average Total Stockholders Equity over the quarter that ended in Mar. 2024 was $4.74 Mil. Therefore, NexGel's annualized ROE % for the quarter that ended in Mar. 2024 was -71.95%.

The historical rank and industry rank for NexGel's ROE % or its related term are showing as below:

NXGL' s ROE % Range Over the Past 10 Years
Min: -1003.99   Med: -179   Max: -48.13
Current: -56.64

During the past 8 years, NexGel's highest ROE % was -48.13%. The lowest was -1,003.99%. And the median was -179.00%.

NXGL's ROE % is ranked worse than
78.95% of 803 companies
in the Medical Devices & Instruments industry
Industry Median: -0.27 vs NXGL: -56.64

NexGel ROE % Historical Data

The historical data trend for NexGel's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NexGel ROE % Chart

NexGel Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -581.85 -1,003.99 -70.91 -48.13 -51.19

NexGel Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -44.96 -42.68 -37.04 -84.50 -71.95

Competitive Comparison of NexGel's ROE %

For the Medical Instruments & Supplies subindustry, NexGel's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NexGel's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NexGel's ROE % distribution charts can be found below:

* The bar in red indicates where NexGel's ROE % falls into.



NexGel ROE % Calculation

NexGel's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-3.157/( (7.637+4.697)/ 2 )
=-3.157/6.167
=-51.19 %

NexGel's annualized ROE % for the quarter that ended in Mar. 2024 is calculated as

ROE %=Net Income (Q: Mar. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Mar. 2024 ))/ count )
=-3.412/( (4.697+4.788)/ 2 )
=-3.412/4.7425
=-71.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. ROE % is displayed in the 30-year financial page.


NexGel  (NAS:NXGL) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-3.412/4.7425
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-3.412 / 5.064)*(5.064 / 10.17)*(10.17 / 4.7425)
=Net Margin %*Asset Turnover*Equity Multiplier
=-67.38 %*0.4979*2.1444
=ROA %*Equity Multiplier
=-33.55 %*2.1444
=-71.95 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2024 )
=Net Income/Total Stockholders Equity
=-3.412/4.7425
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-3.412 / -3.62) * (-3.62 / -3.484) * (-3.484 / 5.064) * (5.064 / 10.17) * (10.17 / 4.7425)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9425 * 1.039 * -68.8 % * 0.4979 * 2.1444
=-71.95 %

Note: The net income data used here is four times the quarterly (Mar. 2024) net income data. The Revenue data used here is four times the quarterly (Mar. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


NexGel ROE % Related Terms

Thank you for viewing the detailed overview of NexGel's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NexGel (NexGel) Business Description

Traded in Other Exchanges
N/A
Address
2150 Cabot Boulevard West, Suite B, Langhorne, PA, USA, 19047
NexGel Inc manufactures high water content, electron beam cross-linked, aqueous polymer hydrogels, or gels, used for wound care, medical diagnostics, transdermal drug delivery, and cosmetics. The company specializes in custom gels by capitalizing on proprietary manufacturing technologies. The gels and consumer products are manufactured using proprietary and non-proprietary mixing, coating, and cross-linking technologies. The company recognizes revenue from contract manufacturing.
Executives
Steven Mark Glassman director 99 LEWIS POINT ROAD, FAIR HAVEN NJ 07704
Nachum Stein director QUADRAX CORP, 618 MAIN ST PO BOX 1001, WEST WARWICK RI 02893
Scott Robert Henry director 34A ATLANTIC AVE., COHASSET MA 02025
David Stefansky director 850 THIRD AVENUE, SUITE 1801, NEW YORK NY 10022
Jerome B Zeldis director 8767 E. VIA DE VENTURA, SUITE 190, SCOTTSDALE AZ 85258
Yaakov Spinrad director 3450 OAKTON ST, SKOKIE IL 60076
Drapczuk Adam E Iii officer: Chief Financial Officer 6 OAKMONT TERRACE, EAST WINDSOR NJ 08520
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Bezalel Partners Llc 10 percent owner C/O KRIEGER & PRAGER LLP, 39 BROADWAY, STE 920, NEW YORK NY 10006
Adam R. Levy officer: CEO and President 2 AVENUE OF TWO RIVER SOUTH, RUMSON NJ 07760
David Ian Johnson director, officer: Chief Executive Officer C/O ALLIQUA, INC., 850 3RD AVENUE, 18TH FLOOR, NEW YORK NY 10022
Adynxx, Inc. 10 percent owner 100 PINE ST., STE. 500, SAN FRANCISCO CA 94111